Tyra Biosciences, Inc. Common Stock (TYRA) is a publicly traded Healthcare sector company. As of July 28, 2026, TYRA trades at $31.55 with a market cap of $1.82B and a P/E ratio of -15.87. TYRA moved +1.44% today. Year to date, TYRA is +18.14%; over the trailing twelve months it is +180.83%. Its 52-week range spans $6.42 to $40.65. Analyst consensus is strong buy with an average price target of $49.88. Rallies surfaces TYRA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Tyra Biosciences and BCAN Launch UTUC Awareness Day, Advance Dabogratinib Phase 2 Study: Tyra Biosciences and the Bladder Cancer Advocacy Network have designated May 21 as Upper Tract Urothelial Cancer Awareness Day to highlight the rarity of UTUC and high FGFR3 mutation rates. Tyra is dosing patients with oral dabogratinib in its Phase 2 SURF303 trial as a kidney-sparing approach for low-grade UTUC.
| Metric | Value |
|---|---|
| Price | $31.55 |
| Market Cap | $1.82B |
| P/E Ratio | -15.87 |
| EPS | $-2.01 |
| Dividend Yield | 0.00% |
| 52-Week High | $40.65 |
| 52-Week Low | $6.42 |
| Volume | 331.59K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-119.95M |
| Gross Margin | 0.00% |
12 analysts cover TYRA: 0 strong buy, 11 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $49.88.